Therefore, we treated 21 R/R DLBCL patients with coadministration of anti‐CD19 and anti‐CD20 CAR‐T cells after lymphodepleting and evaluated the safety and efficacy of the dual‐targeted CAR‐T cell therapy. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.